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Background: Recent research has suggested that the Th1 and Th2 chemokine/cytokine axis contributes to the
development of chronic hypersensitivity pneumonitis (HP). Acute exacerbations (AE) are significant factors in the
prognosis of chronic HP. Little is known, however, about these biomarkers in association with AE in chronic HP
patients.
Methods: Fifty-six patients with chronic HP were evaluated, including 14 patients during episodes of AE. Th1
mediators (C-X-C chemokine ligand [CXCL]10 and interferon [IFN]-γ), Th2 mediators (C-C chemokine ligand [CCL]17,
interleukin-4, and interleukin-13), and pro-fibrotic mediator (transforming growth factor [TGF]-β) were measured to
evaluate the mediators as predictors of AE. C-C chemokine receptor (CCR)4 (receptor for CCL17)-positive
lymphocytes were quantified in lung specimens.
Results: Serum CCL17 levels at baseline independently predicted the first episode of AE (HR, 72.0; 95% CI, 5.03-
1030.23; p = 0.002). AE was significantly more frequent in the higher-CCL17 group (≥285 pg/ml) than in the lower-
CCL17 group (<285 pg/ml) (log-rank test, p = 0.0006; 1-year incidence: higher CCL17 vs. lower CCL17, 14.3% vs.
0.0%). Serum CCL17 levels and CCR4-positive cells during episodes of AE were increased from the baseline (p = 0.01
and 0.031).
Conclusions: Higher serum concentrations of CCL17 at baseline may be predictive of AE in patients with chronic
HP, and CCL17 may contribute to the pathology of AE by inducing the accumulation of CCR4-positive lymphocytes
in the lungs.
Keywords: Chronic hypersensitivity pneumonitis, Acute exacerbations, CCL17/thymus- and activation-regulated
chemokine, C-C chemokine receptor 4Background
Acute exacerbations (AE) have been recognized as a major
complication in the prognosis of idiopathic pulmonary fi-
brosis (IPF) over the last decade [1-4]. AE can also occur
during the course of chronic hypersensitivity pneumonitis
(HP), and when it does it exhibits a clinical course similar
to that in IPF [5-7]. Our group has recently shown that
patients with a usual interstitial pneumonia (UIP) pattern
have a poor prognosis in chronic HP [7].* Correspondence: miyazaki.pilm@tmd.ac.jp
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reproduction in any medium, provided the orEarlier results from our group suggested that the Th2-
predominant immune response may play an important
role in the development of the UIP pattern in chronic
HP [8]. Barrera et al. observed a skewing of Th2 activity,
a likely cause of fibrotic processes, in patients with
chronic HP [9]. Th1 and Th2 cells are thought to play a
pivotal role in fibrogenesis [10]. Investigators can measure
the Th1/Th2 balance by evaluating chemokine receptors
on T cells, using C-X-C chemokine receptor (CXCR)3 as a
marker for Th1 cells and C-C chemokine receptor (CCR)4
as a marker for Th2 cells [11]. In a bleomycin mouse
model, C-C chemokine ligand (CCL)17, the ligand of
CCR4, contributed to the development of pulmonaryl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ligand (CXCL)10 played non-redundant roles in attenuat-
ing fibrosis [13,14].
Biological markers of pulmonary fibrosis are important
in a clinical setting. Prasse et al. recently showed that
baseline levels of serum CCL18 are strong predictors of
death in IPF patients [15]. They concluded that Th2-type
chemokines were significant biomarkers of pulmonary
fibrosis, as CCL18 is produced by M2 macrophages acti-
vated by Th2 cytokines. Similarly, previous human and
animal studies of our own suggest that a Th2-skewed
immune response has a crucial role in the clinical
course of chronic HP [8,16].
Looking at this evidence, we hypothesized that the
Th1/Th2 balance varies throughout the clinical course
of chronic HP and that an immune response skewed
toward Th2 is predictive of AE. In the present study we
evaluated the utility of Th1 mediators (interferon [IFN]-γ
and CXCL10), Th2 mediators (CCL17, interleukin [IL]-4,
and IL-13), and pro-fibrotic mediator (transforming
growth factor [TGF]-β) as predictors of AE in chronic HP.
CCR4-positive lymphocytes with reference to the patho-
genesis of chronic HP with AE were also assessed. We
showed that the baseline serum level of CCL17 was the




Patients who fulfilled all of the criteria for chronic HP at
Tokyo Medical and Dental University Hospital from
1993 to 2009 were recruited. Among them, 56 patients
with chronic bird fanciers’ lung (BFL), a type of HP, were
enrolled as subjects. Some of the patients died and were
autopsied. We reviewed the medical records and BAL pro-
files, and collected blood and BAL samples from all pa-
tients as baseline data at first admission. All of the
patients underwent surgical lung biopsies. Thirty-seven
patients tested positive in an inhalation provocation test
and the other 19 tested positive in an environmental
provocation test [17]. Most of the subjects had been in-
cluded in previous studies by our group. No patients had
medical histories of atopic dermatitis or bronchial asthma.
Eleven healthy volunteers (HV) with no atopic medical
history were enrolled as controls. The study conformed to
the Declaration of Helsinki and was approved by the in-
ternal review board of Tokyo Medical and Dental Univer-
sity Hospital (approval number: 514).
Criteria
The diagnostic criteria for chronic BFL included the
following: 1) a history of avian contact, 2) antibodies and/
or lymphocyte proliferation against avian antigens, 3) re-
production of the symptoms of HP by an environmentalprovocation or a laboratory-controlled inhalation of
avian antigens [18], 4) progressive deterioration of a re-
strictive impairment on pulmonary function for at least
1 year, 5) respiratory symptoms related to HP for at
least 6 months, and either 6) evidence of pulmonary fi-
brosis with or without granulomas on histopathological
analysis or 7) honeycombing on computed tomography
(CT) scans [19,20].
The criteria of Kondoh et al. were used to define AE [21].
1) exacerbation of dyspnea for a duration of no more than
1 month, 2) hypoxemia with an arterial oxygen/fraction
of inspired oxygen ratio (PaO2/FIO2) of < 225, 3) newly
developed pulmonary infiltrates on chest radiography and
4) the absence of apparent infection or heart disease.
Imaging
High- resolution computed tomography (HRCT) was
performed with standard technical parameters at the time
of diagnosis. Three pulmonary specialists (Y.M., K.U., T.T.)
analyzed HRCT findings without knowledge of the pa-
tients’ clinical course and the Kazernooni score for fibrosis
pattern and ground glass pattern was evaluated [22].
Bronchoalveolar lavage (BAL)
We performed BAL as previously described, using three
50 ml aliquots of sterile 0.9% saline solution [8]. The
cellular composition of the BAL was determined with a
cytospin smear with a Wright stain and counting 200
cells. Lymphocyte phenotyping was performed by flow
cytometry with monoclonal antibodies for CD3, CD4
and CD8.
Measurements of CXCL10, CCL17, IFN-γ, IL-4, IL-13, and
TGF-β
Levels of CXCL10, CCL17, IFN-γ, IL-4, IL-13 and TGF-
β were measured in diluted (1:5) serum samples at ei-
ther baseline (AE: n = 14, NAE: n = 42) or at indicated
times and in undiluted BALF samples at either baseline
(AE: n = 11, NAE: n = 37) or at indicated times. TGF-β1
was measured after converting latent TGF-β1 to active
TGF-β1 by acidification. Although measuring active
TGF-β1 is a better method to assess its physiological ef-
fect, we measured total TGF-β1 to evaluate this mediator
as a predictor of AE because we could not detect the
active form of TGF-β1 in most of the samples in this
study. All measurements were performed using commer-
cial immunoassays (Duoset, R & D Systems, Minneapolis,
MN, USA), according to the manufacturer’s instructions.
Histopathological evaluation
Lung tissues were obtained by video-assisted thoracoscopic
surgery. Histological sections of biopsy materials were
stained with hematoxylin-eosin and Elastica van Gieson.
Histological examinations were interpreted by two
Table 1 Patient demographics at baseline†








VC,% predicted 68.6 (38.7-114.0) 80.7 (37.6-130.9) 0.279
PaO2, mm Hg 78.0 (49.8-94.1) 79.0 (47.6-98.0) 0.547
A-aDO2, mm Hg 18.1 (2.4-46.4) 17.4 (9.7-56.8) 0.622
KL-6, U/ml 1500 (867–5450) 1430 (319–8920) 0.737
SP-D, ng/ml 436.5(136–536) 236.5(49–934) 0.101
Fibrosis score 2.4 (0.8-2.9) 1.8 (0.0-3.8) 0.426






No treatment 0 9
CS 4 19
CS + I 10 10
N/A 0 4
Follow-up (months) 27.5 (5–128) 53.0 (2–162) 0.055
Definitions of abbreviation: AE acute exacerbations of chronic HP, NAE non-
exacerbations of chronic HP, VC vital capacity, PaO2 partial pressure of carbon
dioxide in arterial blood, A-aDO2 alveolar-arterial oxygen difference, KL-6 Krebs
on den Lungen-6, SP-D surfactant protein-D, UIP usual interstitial pneumonia,
fNSIP fibrotic nonspecific interstitial pneumonia, cNSIP cellular nonspecific
interstitial pneumonia, CS corticosteroid only, I immunosuppressant, N/A
not available.
†Data are given as the median (range; minimum data-maximum data)
or numbers.
*: p < 0.05.
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blinded to the patient’s clinical information. Histologic
patterns of lung specimens were classified according to
the ATS/ERS international consensus classification as
having a UIP pattern, a NSIP pattern, or an organizing
pneumonia (OP) pattern, based on the quality of fibrotic
changes, which included loose and dense fibrosis and the
temporal appearance [1,23,24]. Patients with NSIP were
subdivided into two groups: those with a cellular NSIP
(cNSIP) pattern and those with a fibrotic NSIP (fNSIP)
pattern [17].
Immunohistochemical analysis
Paraffin sections (4-μm thick) from surgical lung biopsies
and autopsies were prepared for immunohistochemistry.
The following were used as primary monoclonal anti-
bodies: CCL17 (R & D Systems), CCR4 (courtesy of
Kyowahakko, Tokyo, Japan) and CD3 (DAKO Japan,
Tokyo, Japan). Immunoperoxidase staining was performed
as previously described [8]. For immunofluorescent stain-
ing, we used Alexa 488- or Alexa 546-conjugated
streptavidin (Molecular Probes, Eugene, OR, US) instead
of the ABC reagent. Fluorescent staining was analyzed
using a FluoView 500 confocal microscope (Olympus,
Melville, NY) at the Tokyo Medical and Dental University
Imaging Facility.
Semiquantification of CCR4-positive cells
Positive stains for infiltrating cells by anti-CCR4 immuno-
histochemistry were separately counted for fibrosing areas
and for lymphoid clusters from surgical lung specimens
and autopsy lung specimens, as previously described [8].
Positive cells were counted from 20 randomly selected
high-power (400x) fields (HPFs) from fibrosing areas and
from 5 HPFs from lymphoid clusters. Immunohistochem-
istry for CD3 was also performed on each serial section of
the CCR4-stained sections to detect all T lymphocytes in
the same fields and to enumerate the percentage of CCR4-
positive cells among the T lymphocytes. The CCR4 results
were expressed as the percentage of CD3 cells in the same
field.
Statistical analysis
The data were analyzed using GraphPad Prism version
5.0d (GraphPad Software Inc., San Diego, CA, US) and
the R statistical software (http://www.r-project.org/).
Values were expressed as medians and ranges, and a
statistical significance level of 0.05 was used. The AE
and NAE groups, or baseline and AE episodes were
compared using the Mann-Whitney’s U test. Compari-
sons between groups were performed using χ2 or Fisher’s
exact tests for categorical variables. The percentages of
CCR4-positive cells at baseline and during an AE epi-
sode were compared using the Wilcoxon matched-pairssigned-rank test. In a receiver operating characteristic
(ROC) analysis using the first episode of AE as an end-
point, the optimal cut-off point for serum CCL17 con-
centrations was defined as the point closest to the upper
left corner of the ROC curve. Cox proportional hazard
models were used to find the relationship between the
first episode of AE and putative prognostic variables at
baseline after adjustment for age, gender, smoking status,
and the predicted vital capacity (VC) percent.
Results
Clinical features of chronic HP with AE
The baseline characteristics of the patients enrolled by
diagnostic criteria for chronic HP are summarized in
Table 1. Of the 56 chronic HP patients enrolled, 14
(25%) were admitted for acute deterioration of the
disease (AE group) and other 42 cases had experienced
Figure 1 Analysis of prognostic value of baseline serum CCL17.
A: Receiver operating curve analysis of baseline CCL17 levels using
the first episode of AE as an endpoint (p = 0.02, AUC = 0.77). B: Box
and whisker plots of baseline concentrations of CCL17 in AE and
NAE groups, and healthy volunteers (HV) as a reference. The dotted
line represents the cutoff value for predicting AE. C: The incidence of
acute exacerbations grouped by baseline serum concentrations. The
black line represents the chronic HP patients with baseline serum
CCL17 concentrations above 285 pg/ml. The gray line represents the
chronic HP patients with baseline serum CCL17 concentrations
under 285 pg/ml (log rank test, p = 0.0006).
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gender were observed between the AE and NAE groups,
but AE was more likely to develop in ever smokers than
in never smokers (p = 0.089). No significant differences
between the two groups were found in the pulmonary
function tests, in KL-6 and SP-D, biomarkers for inter-
stitial pneumonia, or in HRCT findings on fibrosis and
ground-glass scores. Histologically, the surgical lung speci-
mens from the AE group had significantly more UIP
patterns than the specimens from NAE group (p = 0.024).
Patients received either corticosteroid (CS) alone, CS with
immunosuppressants (IS) (cyclophosphamide [CPA] and
cyclosporine A [CYA]), or no treatment. As no standard-
ized or prospective treatment regimen was applied, the
patients in the AE group received the combination therapy
of CS and IS more frequently than they received no ther-
apy or CS alone (p = 0.02). Meanwhile, a more fibrotic
histological pattern (UIP > fNSIP > cNSIP) was correlated
with a more intensive therapy (CS + IS > CS > no treat-
ment) (r = 0.31, p = 0.026) in all patients. The median
follow-up period was suggestive to be shorter in the AE
group (27.5 months) than in the NAE group (53.0 months)
(p = 0.055). Twenty-one of the 56 patients were lost to
follow up because of transfer to other hospitals during the
observation period, and the median follow-up period for
these patients was 58 months. Twenty-three patients died
during the follow-up period: 12 by AE, 6 by infection, and
5 by chronic progressive respiratory failure. The patients
with AE tended to have fewer lymphocytes in their BALF
(p = 0.085) than the patients in the NAE group (Table 2).
Th1/Th2 chemokines and cytokines in serum and BALF at
baseline
Of the serum markers, the levels of CCL17 and IL-4
were significantly higher in the AE group than in the
NAE group (AE vs. NAE: CCL17, 450.8 [29.4-1450] vs.
132.9 [5.3-1189], p = 0.003; IL-4, 14.0 [0.0-73.7] vs. 13.0
[0.0-43.9], p = 0.036). There were no differences in
CCL17 levels between the NAE group and healthy vol-
unteers (NAE vs. HV: 116.7[5.3-1189] vs. 112.3[0.0-193.6],
p = 0.468) (Figure 1B). In the BALF examinations,
the levels of TGF-β·were significantly higher in the
NAE group (387.3 [0.0-1782]) than in the AE groupTable 2 Profile of BAL at baseline†
Variables AE group (n = 11) NAE group (n = 37) p value
Total cells, x106 31.2 (12.7-58.7) 32.7 (5.6-114.3) 0.986
Macrophages, % 74.7 (33.7-93.0) 57.4 (14.0-98.0) 0.155
Lymphocytes, % 20.5 (5.0-62.2) 26.0 (2.0-86.0) 0.085
Neutrophils, % 1.6 (0.0-25.3) 1.6 (0.0-51.8) 0.484
Eosinophils, % 0.8 (0.0-20.5) 0.8 (0.0-18.8) 0.602
CD4/CD8 ratio 2.2 (0.5-19.5) 2.1 (0.2-15.8) 0.939
†Data are given as the median (range; minimum value-maximum value).(0.0 [0.0-796.1]) (p = 0.042) (Table 3). However, only
one AE sample demonstrated detectable levels of
TGF-β in BALF.
Prognostic value of baseline serum CCL17 concentrations
for predicting the first episode of AE
ROC analysis was performed to test whether baseline
serum CCL17 concentrations were predictive of the first
episode of AE. Baseline serum CCL17 concentrations
had a significant relationship with the first episode of AE
(p = 0.002 and AUC = 0.77, Figure 1A). The cut-off point
for serum CCL17 concentrations was determined to be
285 pg/ml (sensitivity, 0.77; specificity, 0.73, Figure 1B).
Accordingly, we divided the patients into two groups; a
higher-CCL17 group (n = 20, baseline CCL17 concentra-
tions ≥ 285 pg/ml) and a lower-CCL17 group (n = 36,
baseline CCL17 concentrations < 285 pg/ml). The inci-
dences of AE for the two groups were plotted using a
Kaplan-Meier survival curve (Figure 1C). The 1-year and
2-year incidences of AE were 14.3% and 30.1% in the
higher-CCL17 group, versus 0.0% and 3.3% in the lower-
Table 3 Chemokines and cytokines in serum and BALF†
Variables AE group (n = 14) NAE group (n = 42) p value
Serum CXCL10 (pg/ml) 53.9 (18.9-210.1) 74.9 (2.8-1493.8) 0.291
Serum CCL17 (pg/ml) 450.8 (29.4-1450) 132.9 (5.3-1189) 0.003**
Serum IL-4 (pg/ml) 14.0 (0.0-73.7) 13.0 (0.0-43.9) 0.036*
Serum IL-13 (pg/ml) 148.3 (0.0-974.7) 144.6 (0.0-550.7) 0.622
Serum TGF-β (ng/ml) 23.4 (4.5-299.5) 18.8 (1.7-172.2) 0.272
Serum IFN-γ (pg/ml) ND ND
Variables AE group (n = 11) NAE group (n = 37) p value
BALF CXCL10 (pg/ml) 59.0 (24.1-160.4) 83.7 (9.1-733.7) 0.624
BALF CCL17 (pg/ml) 8.1 (0.0-38.9) 5.9 (0.0-32.9) 0.233
BALF IL-4 (pg/ml) ND ND
BALF IL-13 (pg/ml) 31.4 (0.0-241.2) 68.7 (0.0-290.4) 0.851
BALF TGF-β (ng/ml) 0.0 (0.0-796.1) 387.3 (0.0-1782) 0.042*
BALF IFN-γ (pg/ml) ND ND
Definitions of abbreviation: ND not detected, NS not significant.
†Data are given as the median (range; minimum value-maximum value).
*: p < 0.05, **: p < 0.01.
Table 4 Univariate Cox proportional hazard model
evaluating the incidence of AE
Hazard ratio 95%CI p value
Age, yr 1.04 0.98 1.11 0.200
Gender (male = 1) 2.59 0.81 8.34 0.110
Positive smoking history 1.81 0.20 16.20 0.600
VC, % predicted 0.99 0.96 1.01 0.220
CXCL10 0.99 0.98 1.00 0.130
CCL17 (binary) 5.42 1.69 17.30 0.004**
CCL17 (continous) 1.00 1.00 1.00 0.003**
IL-13 1.00 1.00 1.00 0.980
IL-4 1.02 1.00 1.05 0.068
TGF-β 1.00 1.00 1.00 0.072
Definition of abbreviation: CI; confidence interval.
Cutoff point of binary CCL17: 285 pg/ml.
**: p < 0.01.
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higher-CCL17 group than in the lower CCL17 group
(Figure 1C, log-rank test, p = 0.0006).
Factors predictive of the first episode of AE evaluated by
Cox proportional hazard models
We explored how robustly chemokines and cytokines
predicted an upcoming episode of AE. In the univariate
model, a baseline serum CCL17 above 285 pg/ml (binary
response for CCL17) was associated with an increased
risk of AE (hazard ratio [HR], 5.42; 95% CI, 1.69-17.30;
p = 0.004), but no such association was found in any of
other chemokines or cytokines in serum (Table 4).
Multivariate analyses were performed on two models
with the same set of variables, namely, CCL17, CXCL10,
IL-4, IL-13, TGF-β, age, gender, positive smoking history
and VC%. The response for CCL17 was binary in Model
1 and continuous in Model 2. None of the baseline
demographic or pulmonary function variables (e.g. age,
gender, positive smoking history, VC%) were significant
in either model. In Model 1, CCL17 (binary response)
had a p value of 0.002 and an HR of 72.00 with a 95%CI
(5.03-1030.23). This was highly significant. In Model 2,
CCL17 (continuous response) had a p value of 0.038 and
an HR of 1.0023 with a 95%CI (1.0001-1.0045).
Immunohistological localization of CCL17 and CCR4 in
surgical lung specimens
In the surgical biopsy specimens at the time of diagnosis
in 14 AE patients, a UIP pattern was frequently ob-
served; 12 patients had a UIP pattern and 2 patients had
a NSIP pattern (Table 1). A low-power microscopic view
(Figure 2A) showed the UIP pattern, including the
subpleural fibrosis with alternating normal alveoli,fibroblastic foci and honeycomb changes. Lymphocyte
aggregations were observed mainly in the fibrotic le-
sions; however, no granuloma and no NSIP patterns
were revealed.
We evaluated the role of CCL17 in the lungs by
performing immunohistochemistry for CCL17 and CCR4
on surgical lung specimens (7 patients from the AE group
and 16 patients from the NAE group). Intense CCL17
immunostaining was found in epithelial cells (Figure 2B,
2C, 2D, and Additional file 1: Figure S1A), while CCL17-
positive cells were rarely observed in lymphoid clusters
(Figure 2D, 3C, and Additional file 1: Figure S1B). CCR4-
positive cells can be observed more often in fibrotic lesion
than in lymphoid clusters, and CCR4-positive cells are
clustered together in proximity to CCL17-positive cells in
fibrotic area and fibroblastic foci but not in lymphoid
Figure 2 Representative picture and immunohistochemistry of CCL17 and CCR4 in the surgical lung biopsy specimen from AE patient.
A: Low-power microscopic view, haematoxylin-eosin stain. Magnification, 1.5×. Bar = 2000 μm. B, C and D: Immunohistochemistry (IHC) of CCL17
and CCR4. B, fibrosing area and fibroblastic foci, 200×; C, fibroblastic foci, 200×; and D, lymphoid cluster, 100x. For IHC, red represents CCL17
staining and brown represents CCR4 staining.
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and S1B). The CCL17-positive cells were morphologically
identified as bronchiolar epithelial cells and hyperplastic
epithelial cells. The percentage of CCR4-positive cells in
fibrosing areas was significantly higher in specimens from
the AE group than in specimens from the NAE group
(Figure 4A, p = 0.035). Meanwhile, we found suggestive
difference between the AE and NAE groups in the
percentage of CCR4-positive cells in lymphoid clusters
(Figure 4B, p = 0.088). The correlation between the
serum CCL17 concentration and the percentage of
CCR4-positive cells was positive by Spearman’s rank
correlation test (vs. CCR4+ cells in lymphoid clusters, r =
0.520, p = 0.005, CCR4+ cells in fibrosing area, r = 0.415,
p = 0.032).
Comparison of serum CCL17 and CCR4-positive cells
between at baseline and during the episode of AE
The representative image, Figure 5A is an image of the
autopsy lung from the same patient as shown in Figure 2.
The image revealed a UIP pattern, dense subpleural
atelectatic fibrosis and honeycomb changes. The lympho-
cyte accumulations were loose compared with the surgical
biopsy specimens as shown in Figure 2A.
In autopsy specimens from cases who died during AE
episodes, CCL17 was expressed in epithelial cells and
fibroblasts (Figure 5B, C, and D). Many more CCR4-positive cells were observed in both the fibrotic area and
the lymphocyte accumulation area compared with the
surgical lung specimen in Figure 2A. CCR4- and CCL17-
double-positive cells were present in fibrosing areas from
the autopsy specimens with AE (indicated by white arrow-
heads in Figure 6). Paired samples were measured at base-
line and during AE in 11 patients from the AE group.
Serum CCL17 concentrations were significantly increased
during AE compared to the baseline (p = 0.01) (Figure 7A).
Immunohistochemistry for CCR4 was performed on
paired lung specimens at the time of diagnosis and during
an AE episode in 6 patients. The percentage of CCR4-
positive cells was significantly higher during AE than at
baseline in lymphoid clusters and in fibrosing areas
(Figure 7B and C; p = 0.031 and p = 0.031, respectively).Discussion
This study assessed potential associations between Th1/
Th2 biomarkers and AE episodes in patients with chronic
HP. We found that the baseline CCL17 concentration
was an independent predictor of the first episode of AE.
Furthermore, CCR4-postitive cells were significantly in-
creased in lung specimens from the AE group compared
to those from the NAE group at the time of diagnosis,
and CCL17 and CCR4 levels were significantly in-





Figure 3 Immunofluorescent of CCL17 and CCR4 in the surgical lung biopsy specimen of AE patients. Locations of critical structures are
as follows: A, fibrosing areas; B, fibroblastic foci; and C, lymphoid clusters. In merged images, red represents CCL17 staining, green represents
CCR4 staining, and blue represents nuclear staining. Epithelial cells are outlined with arrowhead. Magnification, 1200x. NC: negative control.
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we clearly showed that a cut-off point of 285 pg/ml in
serum CCL17 was an independent indicator of the in-
cidence of AE in chronic HP patients that we studied.
A binary classification test with a sensitivity of 0.77
and specificity of 0.73 is not sufficient, as this fails to
identify about 30% of the patients at risk (Figure 1B).
We can, however, identify about 70% of the AE candidate
at the time of diagnosis. While no markers stronglyFigure 4 Comparison of CCR4-positive cells in the lungs
between AE patients and NAE patients. Comparison of CCR4-
positive cells in fibrosing areas (A, p = 0.035) or in lymphoid clusters
(B, p = 0.088) in surgical lung biopsy specimens taken from the AE
group compared with the same in specimens taken from the
NAE group.predictive of AE are yet available, vigorous investigations
by numerous researchers have identified ST2 [25], α-
defensins [26] and circulating fibrocytes [27] in peripheral
blood as biomarkers for AE. In an earlier study we found
that the baseline serum CCL17 is higher in patients with
UIP patterns than in patients with NSIP pattern [8], and
findings from the present study identified the UIP pattern
as a good predictor of AE (Table 1). Accordingly, we
performed a ROC curve analysis in patients with UIP
patterns to clarify the effect of the underlying histological
patterns. As it turns out, the baseline serum CCL17 is
significantly associated with AE in UIP patients, and the
strength of the association is similar to that in patients in-
cluding all histological patterns (UIP pattern, AUC = 0.74,
p = 0.035 vs. all histological patterns, AUC = 0.77, p =
0.002) (Figure 1A). From the viewpoint of safety, surgical
lung biopsy to identify the histological patterns is invasive
and elevates the risk of AE. Serum biomarkers, on the
other hand, can be sampled easily and safely.
CCL17 is a Th2 chemokine mainly produced by epi-
thelial cells during allergic pulmonary inflammation
[12,28]. CCL17 is established to be involved in three
Th2-dominant diseases: bronchial asthma, atopic derma-
titis, and eosinophilic pneumonia [29]. Increased concen-
trations of CCL17 are initially found in the BAL fluid of
IPF patients, which suggests that CCL17 is involved in the
Figure 5 Representative picture of autopsy lung specimen form AE patient. The images of the autopsy lung from the same patient as
Figure 2. A: Low-power microscopic view, haematoxylin-eosin stain. Magnification, 1×. Bar = 2000 μm. B, C and D: Immunohistochemistry (IHC) of
CCL17 and CCR4. B, fibrosing areas, 200×; C, fibroblastic foci, 200×; and D, lymphoid clusters, 200×. For IHC, red represents CCL17 staining and
brown represents CCR4 staining.
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[12,30]. Regarding chronic HP, we showed that elevated
levels of CCL17 may contribute to the development of
UIP histological patterns [8]. Increased serum CCL17
levels at baseline were predictive of AE in chronic HP in
the present study. The elevated CCL17 in this population
may be partly linked to a continuous and unrecognized
exposure to low-dose avian antigens through sources suchNC
CCL17 CCR4
Figure 6 Immunofluorescent of CCL17 and CCR4 in the autopsy lung
green represents CCR4 staining, and blue represents nuclear staining. Magnas feather duvets, pet birds in the office, pigeons raised by
neighbors, flocks of pigeons or wild birds in parks, shrines
and railway stations. A detailed environmental survey by
site visits confirmed that all of the AE patients investigated
had been unanimously exposed to these sources, whereas
most of the NAE patients visited had not (unpublished
data). Continued antigen exposure of this type could skew
a patient’s Th1/Th2 balance towards Th2. In anothermergenuclei
s of AE patients. In merged images, red represents CCL17 staining,
ification, 600×. NC: negative control.
Figure 7 Comparison of Serum CCL17 and CCR4-positive cells between baseline and AE. A: Comparison of serum CCL17 concentrations
between baseline and AE (p = 0.01). B and C: Comparison of CCR4-positive cells in fibrosing areas (B, p = 0.031) and in lymphoid clusters (C, p = 0.031)
in surgical lung biopsy specimens taken at the time of diagnosis compared with the same in specimens taken during an episode of AE.
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http://respiratory-research.com/content/14/1/57paper we reported that longer exposure to bird-antigen
increased Th2 cytokine such as IL-13 [16]. The suggestive
effects of smoking might also be responsible for the
elevated CCL17 in our subjects. Ever smokers were
suggestively frequent in the AE group (p = 0.089).
Long-term smoking per se was found to decrease the
expression of Th1 cytokines in a mouse model of BFL
[31], and to favor the development of Th2 responses
[32]. CCL17 production by BALF cells increases after
smoking in acute eosinophilic pneumonia patients
[29], and elevated CCL17 mRNA levels were observed
in a murine model of cigarette smoke-induced airway
inflammation [33]. Compared to the NAE group, the
AE group had a higher proportion of smokers and a
significant higher proportion of ex-smokers. This may
have been due to involuntary cessation of smoking before
the onset of AE in the AE group because of severely
impaired pulmonary function tests. Virus infection may be
another cause of elevated CCL17. We excluded infections
in all patients by evaluating sputum cultures, blood cul-
tures, and serological findings such as endotoxin, β-D
glucan and cytomegalovirus (CMV). However, we did not
consider other viral species. Wootton et al. have identified
an unexpected virus (torque teno virus: TTV) that was
associated with 33% of acute exacerbations, although they
did not suggest that viral infection was a major cause of
acute exacerbation in IPF patients. It is possible that the
presence of TTV represents a consequence of lung inflam-
mation rather than the cause of AE [34]. In the study of
viral infections, respiratory syncytial virus (RSV) is of
great interest. RSV is a ubiquitous virus that preferen-
tially infects airway epithelial cells, causing asthma ex-
acerbations and severe disease in immunocompromised
hosts. Monick et al. showed that RSV and Th2- biased
environments could synergistically induced CCL17 and
recruit Th2 cells [35].CCR4 is a CCL17 receptor preferentially expressed on
Th2 cells [11]. Patients with IPF have significantly
higher CCR4 expression on BAL CD4 T cells compared
to patients with other interstitial lung diseases such as
sarcoidosis [36]. Our group has shown that CCL17- and
CCR4-positive cells contribute to the pathogenesis of
UIP patterns [8]. Further, a study using Cox regression
hazard models revealed higher mortality risks in cases
with UIP patterns detected by HRCT [37]. These data
prompted us to investigate whether chemokines and
their receptors play a significant role in the pathogenesis
of AE in chronic HP with a UIP pattern. Intense staining
with CCL17 was seen in fibroblastic foci and in bronchi-
olar epithelial cells adjacent to fibrosing areas in pa-
tients with AE, and there was a correlation between
baseline serum CCL17 levels and the accumulation of
CCR4-positive cells in surgical lung biopsies. Mean-
while, we found that serum CCL17 levels and CCR4-
positive cells were both increased during AE versus the
baseline levels (Figure 5). These data suggest that
CCL17 may be involved in fibrogenesis and the develop-
ment of AE via the recruitment of CCR4-positive cells
into the lesions. In the present study we are unable to
show the higher CCL17 levels in association with the
CCR4-positive cells of the lungs. As the protein in BALF
is 100 times less concentrated than that of alveolar
lining fluid [38], it was difficult to detect an elevation in
the alveolar CCL17 concentration. The levels of BALF
CCL17· were considerably low in the AE and NAE
group, 8.1 (0.0-38.9) pg/ml and 5.9 (0.0-32.9) pg/ml,
respectively, and lower than the detectable range in 5 of
11 AE patients and in 19 of 37 NAE patients. Miyazaki
et al. also showed that the serum CCL17 concentration
of patients with sarcoidosis and IPF are higher than in
healthy volunteers despite having undetectable concen-
trations of BALF CCL17 [39].
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http://respiratory-research.com/content/14/1/57This study had several limitations. First, the study was
retrospective. While our results demonstrated a possibility
that CCL17 may be predictive of AE, we will need to con-
duct a prospective study to certify the results. In addition,
there was a significant referral bias in the study popula-
tion, as our hospital is a clinical center for chronic HP.Conclusions
In conclusion, higher serum concentrations of baseline
CCL17 may be a promising predictive marker of AE in
patients with chronic HP, and CCL17 may contribute to
the pathology of AE by inducing the accumulation of
CCR4-positive lymphocytes in the lungs.Additional file
Additional file 1: Figure S1. High-power images of
immunohistochemistry for CCL17 and CCR4 in the surgical lung biopsy
specimen from the AE patient. A: High-power image of Figure 2B,
fibrosing area and fibroblastic foci. Magnification, 400×. B: High-power
image of Figure 2D, lymphoid cluster. Magnification, 400×. Red
represents CCL17 staining, and CCL17-positive cells are indicated by
arrows. Brown represents CCR4 staining, and CCR4-positive cells are
indicated by arrowheads.Abbreviations
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